News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zalicus Inc. (ZLCS) Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain



5/10/2013 11:27:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that preclinical data highlighting its novel, oral ion channel programs for the treatment of pain including Z160, an N-type calcium channel blocker and Z944, a T-type calcium channel blocker were presented at the 32nd Annual Scientific Meeting of the American Pain Society taking place May 8-11, 2013 in New Orleans, LA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES